Institutional & Insider Ownership
5.7% of Bio-Path shares are owned by institutional investors. Comparatively, 17.3% of Avenue Therapeutics shares are owned by institutional investors. 0.7% of Bio-Path shares are owned by insiders. Comparatively, 8.6% of Avenue Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Volatility & Risk
Bio-Path has a beta of -0.33, indicating that its stock price is 133% less volatile than the S&P 500. Comparatively, Avenue Therapeutics has a beta of -0.92, indicating that its stock price is 192% less volatile than the S&P 500.
Valuation and Earnings
This table compares Bio-Path and Avenue Therapeutics”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Bio-Path | N/A | N/A | -$16.08 million | ($1.06) | -0.06 |
| Avenue Therapeutics | N/A | N/A | -$10.38 million | ($0.94) | -0.48 |
Avenue Therapeutics is trading at a lower price-to-earnings ratio than Bio-Path, indicating that it is currently the more affordable of the two stocks.
Profitability
This table compares Bio-Path and Avenue Therapeutics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Bio-Path | N/A | -2,842.40% | -337.48% |
| Avenue Therapeutics | N/A | -471.57% | -296.50% |
Summary
Avenue Therapeutics beats Bio-Path on 7 of the 8 factors compared between the two stocks.
About Bio-Path
Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nanoparticle drug development company in the United States. The company develops products based on DNAbilize, a drug delivery and antisense technology platform that uses P-ethoxy, which is a deoxyribonucleic acid (DNA) backbone modification intended to protect the DNA from destruction. Its lead drug candidate is prexigebersen, which is in Phase II clinical trials for the treatment of acute myeloid leukemia (AML) and myelodysplastic syndrome. It is also developing BP1001-A that is in Phase I clinical trial for the treatment of solid tumors; Liposomal Bcl-2 (BP1002), which is in Phase I clinical trial for the treatment of refractory/relapsed lymphoma and chronic lymphocytic leukemia; and Liposomal STAT3 (BP1003) for treating pancreatic cancer, non-small cell lung cancer, and AML. The company was founded in 2007 and is based in Bellaire, Texas.
About Avenue Therapeutics
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. Its product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; intravenous tramadol for the treatment of post-operative acute pain; and BAER-101 for the treatment of epilepsy and panic disorders. The company was incorporated in 2015 and is based in Bay Harbor Islands, Florida.
Receive News & Ratings for Bio-Path Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bio-Path and related companies with MarketBeat.com's FREE daily email newsletter.
